Skip to main content
Home
Articles
Latest Issue
Issue Archive
Online First
Special Issues
Categories
Anemia Resources
HOPA Corner
Web Exclusives
All Web Exclusives
Cancer, Clearly
Emerging Data and Trends in HR-Positive/HER2-Negative Breast Cancer
Did You Know? Beyond the Data
Case-Based Exchanges
Conference Correspondent
ESMO 2025 - Wrap-Up: Triple-Negative Breast Cancer
ESMO 2025 - Early Breast Cancer
ASCO 2025 - Breast Cancer Faculty Commentary
ASCO 2025 - Wrap-Up: Triple-Negative Breast Cancer
Biosimilar Resources
Managing Adverse Events in Patients Utilizing Antibody-Drug Conjugate Therapy
Voices From ASCO 2025
Interview with the Innovators
Rapid Reactions
FDA Oncology Update
Videos
Press Releases
Quick Quiz
For Authors
Author Guidelines
Symptom Management Overview
Letters to the Editor/Perspectives
Join Our Peer Review
Submit a Manuscript
About
About JHOP
Contact Us
Editorial Policies
Peer-Review Process
Editorial Board
Editorial Process
Advertising Policy
Advertise
Subscribe
Home
Articles
Latest Issue
Issue Archive
Online First
Special Issues
Categories
Anemia Resources
HOPA Corner
Web Exclusives
All Web Exclusives
Cancer, Clearly
Emerging Data and Trends in HR-Positive/HER2-Negative Breast Cancer
Did You Know? Beyond the Data
Case-Based Exchanges
Conference Correspondent
ESMO 2025 - Wrap-Up: Triple-Negative Breast Cancer
ESMO 2025 - Early Breast Cancer
ASCO 2025 - Breast Cancer Faculty Commentary
ASCO 2025 - Wrap-Up: Triple-Negative Breast Cancer
Biosimilar Resources
Managing Adverse Events in Patients Utilizing Antibody-Drug Conjugate Therapy
Voices From ASCO 2025
Interview with the Innovators
Rapid Reactions
FDA Oncology Update
Videos
Press Releases
Quick Quiz
For Authors
Author Guidelines
Symptom Management Overview
Letters to the Editor/Perspectives
Join Our Peer Review
Submit a Manuscript
About
About JHOP
Contact Us
Editorial Policies
Peer-Review Process
Editorial Board
Editorial Process
Advertising Policy
Advertise
Biosimilars
Comparative Safety Analysis of Infliximab with Its Biosimilar Infliximab-dyyb in Pediatric Rheumatic Conditions
Read More
Biosimilars
Multibiomarker Disease Activity Scores as a Biosimilarity Assessment to Compare Biosimilar Infliximab-qbtx with Infliximab-EU in Patients with Active RA
Read More
Biosimilars
Phase 3 TROIKA Results Demonstrate Clinical Similarity Between HD201 and Trastuzumab Reference in HER2-Positive Early Breast Cancer
Read More
Biosimilars
Safety and Clinical Evaluation of Trastuzumab-dttb + Pertuzumab in Patients with HER2-Positive Breast Cancer
Read More
Neuroendocrine Tumors
Avelumab in Unresectable/Metastatic, Progressive Neuroendocrine Neoplasms
Read More
Neuroendocrine Tumors
Efficacy of Checkpoint Inhibitors in Neuroendocrine Neoplasms
Read More
Neuroendocrine Tumors
Phase 2 NICE-NEC Study of First-Line Platinum-Doublet Chemotherapy + Nivolumab in Unresectable Locally Advanced or Metastatic Grade 3 NENs
Read More
Neuroendocrine Tumors
Irinotecan + Cisplatin versus Etoposide + Cisplatin for High-Grade Neuroendocrine Carcinoma of the Lung
Read More
Neuroendocrine Tumors
Temozolomide Alone or Combined with Capecitabine in Metastatic Neuroendocrine Neoplasia
Read More
Neuroendocrine Tumors
Toxicity Profile of Capecitabine/Temozolomide in NETs
Read More
111
112
113
114
115
116
117
Page 114 of 199
Results 1131 - 1140 of 1986
